Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI)

Today's Latest Price: $80.45 USD

1.32 (1.67%)

Updated Jan 25 3:38pm

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DNLI Stock Summary

  • With a price/sales ratio of 403.52, Denali Therapeutics Inc has a higher such ratio than 98.41% of stocks in our set.
  • Over the past twelve months, DNLI has reported earnings growth of 242.5%, putting it ahead of 94.09% of US stocks in our set.
  • As for revenue growth, note that DNLI's revenue has grown -84.08% over the past 12 months; that beats the revenue growth of just 1.65% of US companies in our set.
  • Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are FATE, ARGX, QURE, AUTL, and BBIO.
  • DNLI's SEC filings can be seen here. And to visit Denali Therapeutics Inc's official web site, go to www.denalitherapeutics.com.

DNLI Stock Price Chart Interactive Chart >

Price chart for DNLI

DNLI Price/Volume Stats

Current price $80.45 52-week high $93.94
Prev. close $79.13 52-week low $12.39
Day low $77.61 Volume 341,668
Day high $81.26 Avg. volume 697,194
50-day MA $74.31 Dividend yield N/A
200-day MA $41.50 Market Cap 9.65B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

Latest DNLI News From Around the Web

Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad…

GlobeNewswire | January 11, 2021

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on…

GlobeNewswire | January 8, 2021

Denali Therapeutics Inc. (NASDAQ:DNLI) COO Alexander O. Schuth Sells 70,000 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) COO Alexander O. Schuth sold 70,000 shares of Denali Therapeutics stock in a transaction on Monday, January 4th. The shares were sold at an average price of $74.95, for a total value of $5,246,500.00. Following the completion of the transaction, the chief operating officer now owns 10,686 shares of the company’s […]

Watchlist News | January 8, 2021

Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today

All of a sudden, out of the blue, shares of multiple unrelated stocks began to sell off. As the final hour of trading got under way Wednesday, shares of database software company MongoDB (NASDAQ: MDB) tumbled 4.8%, car charging network operator Blink Charging (NASDAQ: BLNK) fell 7.8%, and biopharmaceuticals Denali Therapeutics (NASDAQ: DNLI) and Ampio Pharmaceuticals (NYSEMKT: AMPE) fell 5.2% and 35.5%. What do these four stocks have in common?

Yahoo | December 23, 2020

Morgan Stanley Stick to Their Buy Rating for Denali Therapeutics

Morgan Stanley Stick to Their Buy Rating for Denali Therapeutics

Investing.com | December 16, 2020

Read More 'DNLI' Stories Here

DNLI Price Returns

1-mo N/A
3-mo 75.35%
6-mo 239.45%
1-year 226.37%
3-year 262.39%
5-year N/A
YTD -3.95%
2020 380.83%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0657 seconds.